Assessment of the Relative Bioavailability of Rotigotine 4.5 mg Transdermal Patch Versus Neupro 2 mg/24 h Patch in Healthy Adults Under Fasting Conditions

The primary objective of this study is to evaluate the **bioavailability** of Rotigotine 4.5 mg (2 mg/24 hrs) transdermal patch compared to the Neupro® 2 mg/24 h transdermal patch in healthy adult volunteers under fasting conditions. This assessment is crucial for determining the relative absorption and systemic availability of the test product compared to the reference product, which can inform dosing and therapeutic equivalence in clinical settings.

The clinical trial involves a study population comprising **healthy subjects** with an age range category code of 3, indicating a specific age group, though the exact ages are not specified. The trial includes both **female** and **male** participants, and it is noted that a vulnerable population is selected. However, the total number of participants is not provided, as the sponsor has not given this information. The trial is a bioavailability study, and as such, it does not focus on a specific medical condition. The selection criteria for the trial population, including any lifestyle considerations such as diet or physical activity, are not detailed in the available data.

The clinical trial is designed as an **open-label**, randomized, crossover, two-period, two-sequence, multiple-dose study. The primary aim is to assess the relative **bioavailability** of Rotigotine 4.5 mg (2 mg/24 hrs) transdermal patch compared to Neupro® 2 mg/24 h transdermal patch in 48 healthy adult volunteers under fasting conditions. The trial is categorized under Phase 2 and is expected to commence recruitment on November 4, 2024, with an estimated completion date of December 4, 2024. The study does not target any specific medical condition, as it is a bioavailability study conducted in healthy subjects.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized into one of two sequences for the crossover design. Each participant will receive both the test and reference products in different periods, with a washout phase in between to prevent carryover effects. The study will include multiple follow-up visits to monitor safety, adherence, and pharmacokinetic parameters. The end-of-study visit will conclude the trial, where final assessments will be conducted to ensure participant safety and collect any remaining data.

The expected length of participant involvement is approximately one month, including the screening, treatment, and follow-up phases. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The study is structured to ensure rigorous data collection and analysis, adhering to ethical standards and regulatory requirements.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on November 4, 2024, with an estimated completion date of December 4, 2024. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous clinical standards to evaluate the efficacy of the intervention under investigation. The trial's design and execution will be aligned with the objectives of a Phase 2 study, focusing on the efficacy and safety of the treatment. The trial will be conducted in accordance with regulatory requirements and ethical guidelines to ensure the integrity and reliability of the results.